Delving into the Latest Updates on Immunotherapy(Ruprecht-Karls-Universitat Heidelberg) with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

Immunotherapy(Ruprecht-Karls-Universität Heidelberg)

Target-

Action-

Mechanism-

Therapeutic Areas

Immune System Diseases

Active Indication

Graft Rejection

Inactive Indication-

Originator Organization

Ruprecht-Karls-Universität Heidelberg

Active Organization

Ruprecht-Karls-Universität Heidelberg

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Graft Rejection	Phase 1	-	Ruprecht-Karls-Universität Heidelberg	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2023	Not Applicable	-	-	Thymosin α1+consolidative immunotherapy	(eeibkxapyk) = aubfrbpvbn mfernovuze (qwvcayysva ) View more	Positive	31 May 2023
				Thymosin α1+CCRT	(eeibkxapyk) = vhsgpocblf mfernovuze (qwvcayysva ) View more
ASCO2023	Phase 3	Esophageal Carcinoma \| Advanced gastric carcinoma Adjuvant \| Maintenance	-	Chemo-immunotherapy	gqfigrcxjj(iioybbaylz) = xqcuofzpca clcoehrljm (gxfcittjwt ) View more	Positive	31 May 2023
				Immunotherapy-only	nyvqviepte(bdtcchusha) = acrbbroijw yyljuscdiy (taycvlumzq )
ASCO2022	Not Applicable	Non-Small Cell Lung Cancer	68	Capmatinib	hxgphoodwn(vwcacdqvwe) = aejuiflobc hklabzyqaf (xprznixaea ) View more	Positive	02 Jun 2022
				Immunotherapy-containing regimens	hxgphoodwn(vwcacdqvwe) = wudezzresj hklabzyqaf (xprznixaea ) View more
ESMO2018	Not Applicable	Triple Negative Breast Cancer First line	-	Newly approved therapies (e.g. immunotherapy)	(ailghtgtoa) = hmljqmxtrr obqoygorgy (pflwostduy )	-	22 Oct 2018
				Docetaxel	(ailghtgtoa) = kstnafnqjl obqoygorgy (pflwostduy )
ASCO2018	Not Applicable	Metastatic melanoma	80	Combination ipilimumab and anti-PD1 immunotherapy	rgkrpfltzl(jraeiuaqjg) = Hyperacute toxicities from combination immunotherapy are varied. Many pts require treatment beyond oral steroids and for a prolonged duration, and pts are at risk of further severe tox. xljuawzesh (oqxqzpicac )	-	01 Jun 2018
CRD42018083991 (ASCO2018)	Not Applicable	Hepatocellular Carcinoma Adjuvant	-	Non-immunotherapy	(tlngkvklnr): HR = 0.63 (95% CI, 0.51 - 0.79) View more	Positive	01 Jun 2018
				Immunotherapy
ASCO2016	Not Applicable	Metastatic melanoma	140	Targeted therapy alone (BRAF mutant)	(ihtqbrtuht) = thkbyyzrzv oqtfapwxsb (nyonszjexp )	Positive	20 May 2016
				Targeted therapy combined with chemotherapy and/or immunotherapy (BRAF mutant)	(ihtqbrtuht) = nlyfylijmn oqtfapwxsb (nyonszjexp ) View more
ASCO2004	Not Applicable	Relapsing acute myeloid leukemia \| Acute lymphoblastic leukemia recurrent	97	GM-CSF + IFN	(wbkybccznj) = flxsunrept iejuvgvsig (veorqptjxf )	-	15 Jul 2004
				No cytokine immunotherapy	(wbkybccznj) = bnpuawnfkp iejuvgvsig (veorqptjxf )